2-benzyl-6-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazole | 73667-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-benzyl-6-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazole
• 英文别名: 2-Benzyl-6-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazole
• CAS: 73667-70-6
• 化学式: C₁₇H₁₂ClN₃S
• 分子量: 325.821
• InChiKey: DDEXZELLJOMKGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-benzyl-6-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazole 在 哌啶 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 8.0h， 生成 3-((2-benzyl-6-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylidene)-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain

  摘要：

  The antiapoptotic protein BCL2 is overexpressed in several cancers and contributes to prolonged cell survival and chemoresistance, lending itself as an excellent target for cancer therapy. Here, we report the design, synthesis, and characterization of Disarib, a novel BCL2 inhibitor. Disarib showed selective cytotoxicity in BCL2 high cancer cell lines, and CLL patient primary cells, as compared to BCL2 low cell lines. BCL2 knockdown in cells rendered remarkable resistance to Disarib, while sensitivity was regained upon its ectopic expression, establishing target specificity. In silico, biochemical and biophysical studies demonstrated strong affinity of Disarib to BCL2, but not to other antiapoptotic BCL2 family members viz., BCL‐xL, BCL2A1 etc. Interestingly, biophysical studies showed that BH1 domain deletion mutant demonstrated ~ 67‐fold reduction in BCL2‐Disarib interaction, while it was only ~ 20‐fold in the case of BH3 deletion mutant, suggesting predominant involvement of the BH1 domain for Disarib binding. Thus, we report identification of a novel BCL2 inhibitor with a unique mechanism of BCL2 inhibition, as opposed to the well‐studied BH3 domain targeting.

  DOI：

  10.1111/febs.13815
• 作为产物：
  描述：

  苯乙酸 在 硫酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 7.07h， 生成 2-benzyl-6-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazole
  参考文献：
  名称：

  咪唑并[2,1-b] [1,3,4]噻二唑衍生物的微波辅助合成及抑菌活性

  摘要：

  开发了一种简单有效的方法，用于在微波（MW）活化下使用2-氨基-5-取代-1合成2,6-二取代-咪唑并[2,1-b] [1,3,4]噻二唑， 3,4-噻二唑和适当的溴代酮为原料。所有反应都证明了MW反应的好处：操作方便，反应时间短，产率高。通过IR，NMR和质谱对所有衍生物进行表征。使用杯板法对金黄色葡萄球菌，克雷伯菌和白色念珠菌微生物进行抗菌和抗真菌活性。2-（4-硝基苄基）-6-（4-溴苯基）咪唑并[2,1-b] [1,3,4]噻二唑（4Ce）是唯一对克雷伯菌具有活性的衍生物在低微摩尔浓度（5μg/ ml）下具有中等抑制区域。而2-（4-硝基苄基）-6-（4-氟苯基）咪唑并[2,1-b] [1,3,4]噻二唑（4Cf）作为最有效的抗真菌活性衍生物，相对于50μg/ ml与标准氟康唑比较的白色念珠菌。

  DOI：

  10.1007/s00044-011-9671-8

文献信息

• Synthesis and antiproliferative activity of imidazo[2,1- b ][1,3,4]thiadiazole derivatives
  作者：Sujeet Kumar、Vidya Gopalakrishnan、Mahesh Hegde、Vivek Rana、Sharad S. Dhepe、Sureshbabu A. Ramareddy、Alberto Leoni、Alessandra Locatelli、Rita Morigi、Mirella Rambaldi、Mrinal Srivastava、Sathees C. Raghavan、Subhas S. Karki

  DOI：10.1016/j.bmcl.2014.08.032

  日期：2014.10

  6-substituted imidazo[2,1-b][1,3,4]thiadiazole derivatives have been prepared and were tested for antiproliferative activity on cancer cells at the National Cancer Institute. Results showed that molecules with a benzyl group at position 2, exhibited an increase in activity for the introduction of a formyl group at the 5 position. The compound 2-benzyl-5-formyl-6-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazole

  已经制备了一系列的2,5,6-取代的咪唑并[2,1- b ] [1,3,4]噻二唑衍生物，并在美国国家癌症研究所测试了其对癌细胞的抗增殖活性。结果表明，在2位具有苄基的分子表现出在5位引入甲酰基的活性增加。化合物2-苄基-5-甲酰基-6-（4-溴苯基）咪唑并[2,1- b ] [1,3,4]噻二唑22已通过各种分子和细胞生物学研究选择了理解作用机理的化合物。从细胞周期评估分析，通过流式细胞术分析线粒体膜电位和膜联蛋白V-FITC，ROS产生以及凋亡和DNA修复蛋白表达获得的结果表明，化合物22通过激活细胞凋亡的外在途径诱导细胞毒性。影响细胞周期进程。
• Synthesis, Hypoglycaemic, Hypolipidemic and PPARγ Agonist Activities of 5-(2-Alkyl/aryl-6-Arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene-1,3-Thiazolidinediones
  作者：Mohammed Iqbal A. Khazi、Ningaraddi S. Belavagi、Kwang R. Kim、Young-Dae Gong、Imtiyaz Ahmed M. Khazi

  DOI：10.1111/cbdd.12140

  日期：2013.8

  A novel series of 5‐(2‐alkyl/aryl‐6‐arylimidazo[2,1‐b][1,3,4]thiadiazol‐5‐yl)methylene‐1,3‐thiazolidinediones were synthesized as possible PPARγ agonists. The structures of these target molecules were established by spectral and analytical data. All the newly synthesized compounds were screened for their in vivo hypoglycaemic and hypolipidemic activity in male Wistar rats. Further, compounds with good activity were screened for PPARγ agonist activity. Among the screened compounds, 5‐[2‐Cyclohexyl‐6‐(4‐methoxyphenyl)imidazo[2,1‐b] [1,3,4]thiadiazol‐5‐yl]methylene}‐1,3‐thiazolidine‐2,4‐dione (3i) exhibits promising hypoglycaemic and hypolipidemic activity via potential PPARγ agonist activity.
• Microwave-assisted synthesis and antimicrobial activity of some imidazo[2,1-b][1,3,4]thiadiazole derivatives
  作者：Sharad Dhepe、Sujeet Kumar、R. Vinayakumar、Sureshbabu A. Ramareddy、Subhas S. Karki

  DOI：10.1007/s00044-011-9671-8

  日期：2012.8

  Mass spectroscopy. Antibacterial and antifungal activity was performed using cup plate method against Staphylococcus aureus, Klebsiella, and Candida albicans microorganisms. 2-(4-nitro benzyl)-6-(4-bromo phenyl)imidazo[2,1-b][1,3,4]thiadiazole (4Ce) was the only derivative which showed activity against Klebsiella at low micromolar concentration (5 μg/ml) with moderate zone of inhibition. And 2-(4-nitro

  开发了一种简单有效的方法，用于在微波（MW）活化下使用2-氨基-5-取代-1合成2,6-二取代-咪唑并[2,1-b] [1,3,4]噻二唑， 3,4-噻二唑和适当的溴代酮为原料。所有反应都证明了MW反应的好处：操作方便，反应时间短，产率高。通过IR，NMR和质谱对所有衍生物进行表征。使用杯板法对金黄色葡萄球菌，克雷伯菌和白色念珠菌微生物进行抗菌和抗真菌活性。2-（4-硝基苄基）-6-（4-溴苯基）咪唑并[2,1-b] [1,3,4]噻二唑（4Ce）是唯一对克雷伯菌具有活性的衍生物在低微摩尔浓度（5μg/ ml）下具有中等抑制区域。而2-（4-硝基苄基）-6-（4-氟苯基）咪唑并[2,1-b] [1,3,4]噻二唑（4Cf）作为最有效的抗真菌活性衍生物，相对于50μg/ ml与标准氟康唑比较的白色念珠菌。
• Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain
  作者：Divyaanka Iyer、Supriya V. Vartak、Archita Mishra、Gunaseelan Goldsmith、Sujeet Kumar、Mrinal Srivastava、Mahesh Hegde、Vidya Gopalakrishnan、Mark Glenn、Mahesh Velusamy、Bibha Choudhary、Nagesh Kalakonda、Subhas S. Karki、Avadhesha Surolia、Sathees C. Raghavan

  DOI：10.1111/febs.13815

  日期：2016.9

  The antiapoptotic protein BCL2 is overexpressed in several cancers and contributes to prolonged cell survival and chemoresistance, lending itself as an excellent target for cancer therapy. Here, we report the design, synthesis, and characterization of Disarib, a novel BCL2 inhibitor. Disarib showed selective cytotoxicity in BCL2 high cancer cell lines, and CLL patient primary cells, as compared to BCL2 low cell lines. BCL2 knockdown in cells rendered remarkable resistance to Disarib, while sensitivity was regained upon its ectopic expression, establishing target specificity. In silico, biochemical and biophysical studies demonstrated strong affinity of Disarib to BCL2, but not to other antiapoptotic BCL2 family members viz., BCL‐xL, BCL2A1 etc. Interestingly, biophysical studies showed that BH1 domain deletion mutant demonstrated ~ 67‐fold reduction in BCL2‐Disarib interaction, while it was only ~ 20‐fold in the case of BH3 deletion mutant, suggesting predominant involvement of the BH1 domain for Disarib binding. Thus, we report identification of a novel BCL2 inhibitor with a unique mechanism of BCL2 inhibition, as opposed to the well‐studied BH3 domain targeting.